Labcorp Holdings Inc.

LH · NYSE · ·

Vergleichen

370,57 $-0,5 %Schluss 13. Nov.

Zahlen bis 30. September 2026, aus dem 10-Q vom 30. Oktober 2026

1W: +1,1 %
1M: +16,8 %

Labcorp Holdings Inc. (LH) Aktie — ist das ein gutes Unternehmen? — InspectStocks

Labcorp Holdings Inc.

LH · NYSE · ·

Vergleichen

370,57 $-0,5 %Schluss 13. Nov.

Zahlen bis 30. September 2026, aus dem 10-Q vom 30. Oktober 2026

1W: +1,1 %
1M: +16,8 %

Just reported

Q3 2026 results

From Labcorp's results release of 28. Oktober 2026; its quarterly report has since been filed.

Revenue
Actual
3,81B $
+6,9 % y/y
+2,1 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
3,22 $
+3,2 % y/y
-12 % q/q
Guided
—
No guide given
Operating income, GAAP
Actual
402,1M $
+1,4 % y/y
-11 % q/q
Guided
—
No guide given

Company outlook

Full year 2026

EPS, adjusted18,30 $ – 18,70 $Raised +1,0 %

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Labcorp is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Kuratiert
Lab tools & diagnostics
Von InspectStocks · 20 companies
Instruments, supplies and testing services for labs, drugmakers and doctors.
Kurs, 1 Jahr
+22,4 %
Umsatz, 1 Jahr
+7,8 %
+14
A 8B 8C 2D 1F 1

Highest-graded in Diagnostics and Research

Graded A or B and worth $2B or more: A first, then the largest.

All 42 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Womit das Unternehmen Geld verdient

Diagnostic laboratory testing78 %
Biopharma laboratory services22 %

Die Umsatzanteile sind Schätzungen für year ended 2025-12-31 und keine Zahlen aus einem eingereichten Bericht.

Konkurriert mit

Was es verkauft6

Routine and specialty diagnostic tests
Laboratory tests on patient samples, including tests used to diagnose and monitor diseases, as well as occupational, wellness and forensic deoxyribonucleic acid (DNA) testing.
ColoSense
A stool-based colorectal cancer screening test that people collect at home; it is approved by the U.S. Food and Drug Administration (FDA).
PlasmaDetect genome minimal residual disease (MRD)
A blood test being evaluated for monitoring whether early-stage lung cancer returns after treatment.

3 weitere anzeigen

Labcorp OnDemand
A service through which consumers can order certain health and wellness tests directly, including tests for cancer screening, allergies and men's and women's health.
Central laboratory services
Laboratory testing for pharmaceutical and biotechnology companies conducting clinical studies of medicines.
Early development laboratory services
Laboratory services supporting early stages of drug research and development.

Wer es kauft6

Physicians and medical practices order tests for patients and may receive the bills themselves or direct billing to patients or health plans.
Hospitals and health systems use Labcorp for testing, including outreach laboratory services and tests they send to an outside laboratory.
Health plans and managed care organizations pay for covered tests under negotiated fee schedules or per-member payment arrangements.

3 weitere anzeigen

Medicare and Medicaid pay for eligible tests under government fee schedules.
Patients pay for tests when uninsured, for their share of an insured test, or when they order tests directly.
Pharmaceutical, biotechnology, medical device and diagnostic companies, along with contract research organizations, buy laboratory services under contracts.

Worauf es steht, und was es umwerfen könnte

Wovon das Geschäft abhängt

1Diagnostic revenue depends on reimbursement rules, coverage decisions and negotiated payment rates from health plans and government programs.
2A portion of diagnostic revenue depends on collecting patient balances, including deductibles, coinsurance and bills for uninsured patients.
3Biopharma Laboratory Services depends in part on research and development spending by pharmaceutical, biotechnology and medical device companies.
4Laboratory work depends on qualified staff, laboratory facilities, supplies and third-party transportation and services.

Was schiefgehen könnte

1Changes to government or health-plan coverage and reimbursement, including changes affecting Medicaid or insurance exchanges, could reduce testing volumes or payments. The company has identified possible changes to Medicaid and the Affordable Care Act as a source of potential pressure on diagnostic testing.
2Patients account for a material portion of diagnostic receivables, and Labcorp may collect less than billed when patients cannot or will not pay their share.
3Reduced research and development spending, changes in pharmaceutical or medical-device regulation, or the loss or early termination of contracts could reduce demand for Biopharma Laboratory Services or leave Labcorp with contract costs it cannot recover.

Vollständige Abschlüsse →

Über Labcorp Holdings Inc.

Labcorp tests patient samples at its laboratories, performing routine and specialty tests for diagnosing and monitoring health conditions. Its Biopharma Laboratory Services business performs laboratory work for pharmaceutical, biotechnology, medical device and diagnostic companies, including central laboratory testing and early development services. Patients can also order some tests directly through Labcorp OnDemand.

Hauptsitz: Burlington, North Carolina
Gegründet: 1978
Notiert an: NYSE
Geschäftsjahresende: December 31

Gebaut aus den eigenen Einreichungen von Labcorp Holdings Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.

Just reported